MARVIN Chatbots for Health Information

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on adapting the MARVIN chatbot, originally developed for HIV patients, to provide information for various health conditions such as breast cancer and pediatric emergency medicine. The study employs an adaptive platform trial design, allowing for flexibility in testing multiple chatbot interventions tailored to different populations. Researchers will evaluate the usability and implementation outcomes of these chatbots through co-construction with participants, ensuring the tools meet their needs and encourage ongoing use. The study aims to gather data on factors that influence the effectiveness of the chatbots in real-world scenarios.

Why it matters

Who can join: the full rules

Inclusion Criteria for all objectives:

* being 14 years or older;
* being fluent in English and/or French;
* being able to understand the requirements of study participation and provide informed consent during the duration of the study;
* having access to a smartphone, tablet, or computer at home/at workplace;
* having access to an internet connection at home or data plan on their device.

Inclusion Criteria Specific to objectives 2 and 3:

* accept to use a Facebook Messenger-based Chatbot;
* accept to use or create a personal Facebook account;
* accept Facebook's privacy and data security policies.

Exclusion Criteria:

* not meeting the inclusion criteria
* any reason, in the opinion of the investigator, which would make the candidate inappropriate for participation in an investigative study involving a chatbot (e.g., cognitive deficit)

Where it's running

• Centre hospitalier de l'Université de Montréal (CHUM)
  Montreal, Quebec, Canada Recruiting
• McGill University Health Centre (MUHC)
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Bertrand Lebouché, MD — McGill University Health Centre/Research Institute of the McGill University Health Centre
• Study coordinator: Bertrand Lebouché, MD
• Email: bertrand.lebouche@mcgill.ca
• Phone: 514-843-2090

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.